The Shkreli Pill

Beyond Meat Not Worth the Investment

"I was watching this great video of this great investor from the children\'s investment fund PCI who basically says that 99% of stocks out there are not suitable for his portfolio. And it\'s like such a crazy thing to say, but when you stop and think about it, it\'s really true that there are only a couple percent of the companies in the world that are exceptional and worth investing in. Beyond Meat is not one of them, spoiler alert, but nor are most companies. So why would you want this in your portfolio? You want to make crazy gambles."

The speaker delivers a bearish company commentary on Beyond Meat, asserting that it is not one of the exceptional companies worth investing in. The commentary implies that Beyond Meat, as a startup with a questionable business model, is unsuitable for long positions and should be avoided by conservative investors.

Trade Call on Drug Company Serrea

"I bought a drug company stock recently called Serrea. Serrto is trading at one or two times sales, and in the history of pharmaceuticals it\'s very rare to get these kinds of assets at such multiples. There was still a risk, but it was disproportionately likely that I would profit. In contrast, with Beyond Meat you\'re just playing musical chairs. Unless you can clearly justify why in the long term the stock is worth significantly more, it\'s a gamble."

The speaker presents an explicit trade call for a drug company, Serrea, noting its attractive valuation at one to two times sales. He contrasts this opportunity with riskier plays like Beyond Meat, arguing that Serrea provides a more favorable risk-reward profile.

Buy Call on SKH Highix

"I\'m looking at some Korean stocks and there\'s been a lot of movement in Korea on the AI kind of bubble. Korea is often wildly mispriced, usually awfully cheap. I guess my point is you should always be looking at how to expand your toolkit to new companies, geographies, and sectors. And like SKHix is a really, really good example where SKHix just makes the memory for Nvidia\'s chip. You might have missed the Nvidia rally because if you ask an AI engineer, what\'s the most important part of an Nvidia chip? It\'s actually the memory. And with one Google search or one ChatGPT question, you would learn that it\'s actually SKH Highix and Samsung. Just buying SKH Highix, it\'s gone parabolic."

The speaker highlights SKH Highix as an undervalued play in the Korean market, emphasizing its critical role in producing memory for Nvidia chips. The commentary suggests a strong buy sentiment as the stock has shown parabolic movement recently.

Pessimistic View on Beyond Meat

"The fundamentals never lie. Over the long term, the stock price will always follow the fundamentals. A company like Beyond Meat is absolute poo poo, right? It\'s terrible. They don\'t have any customers. Anybody who doesn\'t like meat isn\'t eating processed chemicals. And anybody who likes meat isn\'t eating Beyond Meat. They\'ve got no customers."

The speaker delivers a scathing commentary on Beyond Meat, arguing that its fundamentals are extremely weak, with a lack of real customers and unsustainable business metrics, implying the stock is destined to perform poorly over time.

Bullish on Tesla Fundamentals

"And they short good companies with good management teams at bad prices. And I really think it\'s the quality of the company and the management team that matters the most. So like everyone who\'s short Tesla I think is making a gigantic mistake because it kind of fundamentally is a good company and it kind of fundamentally a great management team."

The speaker criticizes short sellers targeting Tesla, arguing that despite its high price, Tesla is a fundamentally strong company with an excellent management team. This serves as a warning against shorting what is portrayed as a fundamentally sound stock.

Long SPRB on Rare Disease Catalyst

"Why long SPRB? Well, this is my wheelhouse. Its a rare disease drug company and they have a rare disease from a drug from Biomearin. Biomearin was kind of like the rare disease kings and, um, yeah, basically, um, the drug works, um, really well and, um, itll get FDA approval and itll sell a lot and thats really it. Its worth like 5x what its trading at."

The speaker recommends a long position in SPRB, citing its rare disease focus and the potential for FDA approval as key catalysts. The claim is that the drug is undervalued, trading at approximately one-fifth of its potential value.

Short Beyond Meat Trade

+25.44%current return

"Let me see if I can short some more beyond. I'd short a little bit more beyond at like my average is around six. So short a little more. The bond holders are just shoving the stock in your face and that kind of makes it hard for their stock to rally. That's why I'm short it."

The speaker explicitly calls for increasing a short position in Beyond Meat (BYND), arguing that aggressive actions from bond holders are keeping the stock depressed and inhibiting a rally.

Shorting Beyond Meat on Broken Fundamentals

+25.44%current return

"I just shorted some. My average is 375 now. Um, it's, uh, this had been a profitable short for me years ago. Like, this is just such an AUG company that's like it's so reliable to short it. Um, 'cause again negative growth in terms of size of the portfolio. I think I'm at 1% now. So it would have to go literally 100x for me to be worried about it."

The speaker outlines his short position in Beyond Meat, noting that he has already entered at an average price of 375 and is comfortable keeping a 1% position given the company's persistently broken fundamentals and negative growth. He indicates a willingness to increase his short if the stock shows upward pressure, reinforcing his bearish view on the stock.

Short Trade Call on Beyond Meat due to Overextended Financials

+40.98%current return

"Beyond Meat, um that has rallied what a what a move from it was trading at 8 cents. This is the 2027 paper and it's now 75 cents on the dollar. Incredible, incredible move for the Beyond Meat debt. No real update on Spruce. Same same story. No, Beyond Meat isn't the GameStop of anything. Okay, so they're issuing up to... share outstanding number is wrong. It's not a 200 million market cap. Massive amount of stock. 326,190,370. They like quadruple the shares outstanding. So, what is this business worth? What's the stock price? 356. Um, yeah, the bonds have 10xed. Um, bond holders are allowed to put them into bankruptcy, but now company's kind of back, but you know, there's maybe 40 million in gross profit. I got some short on a different broker. Short at 345."

The speaker outlines a short trade on Beyond Meat (BYND), emphasizing its overblown valuation and financial distortions—quadrupled shares outstanding, inflated debt conversion, and weak gross profit metrics. The detailed rationale, including an executed short at 345, calls the stock a bankrupt candidate with unsustainable fundamentals.

Short Tesla Trade Call

+1.26%current return

"m short Tesla. Why isn"

The speaker highlights an active short position on Tesla, questioning the market behavior in light of his value investing approach. The brevity of the comment contrasts his strong conviction against the stock despite broader market trends.

Short CLSQ and Joby Trade Calls

-4.33%current return

"Plenty of stocks still up a ton. Maybe I should short CLSQ. I'm short Joby as well."

The speaker briefly considers additional short positions by mentioning a potential short on CLSQ along with an existing short on Joby. The comment reflects an opportunistic approach in a volatile market environment.

Short BTQ - Zero Value Warning

-10.57%current return

"e going to owe money. Listen, if you don"

The speaker declares a strong negative view on BTQ, calling the company worthless and predicting it will fall to near zero. The aggressive tone underscores a clear short trade recommendation, warning inexperienced traders.

Short Regetti Trade Call

-0.80%current return

"Expensive, man. I would just keep shorting Regetti. Regetti CEO is presenting at this conference."

The speaker explicitly recommends shorting Regetti, noting that the stock is expensive despite the CEO speaking at a conference. The suggestion implies that the company's fundamentals or valuation might be off.

Bearish Outlook on Publicly Traded Quantum Stocks

+25.53%current return

"And I think that, you know, the four publicly traded quantum stocks are all going to zero. I don't think there's any value in any of these companies. IMQ has tried hard to pivot by using its stock to buy other companies, but fundamentally, these stocks have no revenue and no real future. Even if capital is flowing in now, eventually the market will force a reckoning. It’s a great time to start shorting because capital cycles shift fast."

The speaker delivers a strongly bearish view on publicly traded quantum stocks, asserting that all four listed quantum companies will eventually go to zero due to a lack of revenue and sustainable business models. The emphasis is on the imminent capital cycle reversal, signaling short opportunities for traders.

Bullish Call on ABVX with Target Price of 200

-5.07%current return

"Yeah, one stock I like. Come on, man. Come on. I like a stock called ABVX. I've been long, I've been longing the stock. I think it's going to go to 200. And that's really it. It's a drug company and I believe there’s substantial upside."

The speaker expresses a clear bullish trade call on ABVX, stating a conviction that the stock will rise significantly to a target price of 200. The commentary identifies ABVX as a drug company and implies strong potential, making it an actionable idea for traders.

Trade Call: Buy QBTS at $7

-1.09%current return

"The trade is not buying QBQTs at at 34 bucks. The trade is buying QBTS at $7, riding the first phase of the quantum wave. Then, when it hangs, you rinse and repeat."

The speaker explicitly recommends buying QBTS at $7 as a way to capitalize on the early phase of the quantum computing wave. The emphasis is on entering at a lower price point rather than paying inflated prices, with the plan to exit after the initial surge.

Missed Quantum Trade Entry

+1.09%current return

"I’m not saying buy RTI at $48. So, I’m not seeing buy high Q at as at $70. You’ve already missed a trade when I pulled it at 750. The quantum trade from this perspective has already occurred. In other words, if you’re waiting for an entry at these levels right now, you’re too late."

The speaker offers an explicit trade call regarding quantum-oriented stocks. He dismisses buying RTI at $48 or high Q at $70, asserting that the optimal entry has passed, as he himself entered at 750. This retrospective call highlights his conviction that the quantum play, which involves companies linked to quantum computing and its associated infrastructure, is now a missed opportunity for new entrants.

Immediate Buy Signal for ANAB

"Yeah, I like ANAB. I looked at it. I can do uh I could do four. I could do right now. Yeah, chemistry is good to learn. No need for congratulations."

The speaker expresses a clear and immediate bullish trade call on ANAB, stating a personal readiness to buy at that moment based on a positive qualitative view.

Company Commentary on AMD's AI Accelerator Business

"Our recent conversations across the supply chain point to AMD experiencing slowing progress with its AI accelerator business. We think makes it increasingly challenging for them to meet over high expectations. This year conversations we show signs that AMD is struggling to grow for many of the customers that announced at its AI event this summer. Market remains challenging with highly demanding customers. Many of the headline customers have only purchased evaluation systems that are unlikely to convert into volume orders for at least one generation of MI systems."

The speaker provides an in-depth commentary on AMD, highlighting concerns regarding its AI accelerator business. He notes that despite a high-profile OpenAI-related event, AMD is facing challenges as many customers have only committed to evaluation systems rather than full volume orders, which could hinder future growth.

Speculative Outlook on Unicure Buyout Prospects

"Will my price target what would be your price target for cure in case of a bio here? Let's un let's let's understand this from a linguistics perspective first. What would be your price target for cure in case of a buyout conservatively? That is our question, right? Cure is not a cure for Huntington's to be clear. It's a treatment. It's a potential treatment without exactly definitive control data. So, it's speculative treatment. If a company were to be bought out, I mean, you can't, it doesn't make sense. What would your price target be? I guess what you're trying to ask is, do you think there is a drug company out there willing to pay a premium right now for Unicure stock price? I don't think that's the right way to think about it."

The speaker discusses the idea of setting a price target for Unicure in the event of a buyout. He clarifies that Unicure offers a speculative treatment for Huntington's rather than a definitive cure, emphasizing that drug companies are unlikely to pay a substantial premium without clear data. This commentary highlights the complexities behind M&A expectations and cautions investors against assuming a buyout scenario as a basis for valuation.

Automated Multi-Leg Trade Calls Using Custom Tool

"All right. So, it's telling me Cororeweave is a short microchip and Coreweave are shorts. So, I'm going to go put that trade in. Microchip. And I got a little ledger here. I'm going to use Got to go look up where I got out of actually. sell microchip do a small amount just a 100 shares 584 all right I could copy and paste this instead corweed as well so I'll do that core weed is a bigger stock price I think so I'm going to do less share amount half as much shares so 50 12977 um long that's uh healthcare company Molina so that's even bigger stock pricey uh 203945. Uh what is this one? 40. And then Futu wants me to go long this thing. Some kind of, okay, it's online brokerage. You guys heard of Futu FU TU? I guess I'll buy some."

The speaker details several explicit trade actions generated by his custom automated market analysis tool. He indicates short positions on Coreweave (and selling Microchip with specific share amounts and price references) and long positions on healthcare company Molina and online brokerage Futu. The trades are executed on an intraday basis with short time horizons, reflecting a systematic, quantitative intraday trading strategy.

Short Sound Hound Stock

-11.20%current return

"Sound Hound ... It's a joke. I mean, everyone on Wall Street knows Sound Hound's a scam. I didn't short sound. I'm just saying it's a good short."

The host dismisses Sound Hound as a scam and implies that it is an excellent candidate for a short position, highlighting its lack of credibility and value.

Avoid Long Position in MLTX

-34.46%current return

"MLTX big disappointment 88%. We didn't have the confidence uh either way of position like most of the street. I was thinking it maybe was long. It was not a long."

The speaker expresses strong disappointment with MLTX citing an '88% big disappointment' and explicitly rejects taking a long position on the stock, suggesting caution to investors.